

30 June 2026

## Tender results –2025/26 Invitation to Tender

Pharmac has resolved to award or not award tenders for Principal Supply Status for some products included in the 2025/26 Invitation to Tender dated 3 November 2025.

Some of the Pharmaceuticals that will be delisted when the period of Principal Supply Status commences may be subject to existing listing contracts with Pharmac. Suppliers of Pharmaceuticals that are subject to such contracts should continue to supply their Pharmaceutical under those contracts. Pharmac will continue to subsidise those Pharmaceuticals accordingly until such time as those Pharmaceuticals are delisted.


### Notification of Product Changes (NOPC) forms

Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to submit a Notification of Product Changes (NOPC) form to Pharmac, the Pharmacy Guild and the NZULM by:

- **For new listings**, by 4pm on the 12<sup>th</sup> of July 2026 or the 5<sup>th</sup> of the month prior to listing, whichever is earlier
- **For price changes**, by 4pm on the 12<sup>th</sup> of the month prior to the date of subsidy change

Pharmac cannot list a product (and Pharmacies cannot claim) without this information. More information about this process, and a copy of the NOPC form can be found on our website – <https://pharmac.govt.nz/medicine-funding-and-supply/make-an-application/pharmconnect-make-a-medicine-funding-application/process-for-notification-of-product-changes/>

Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand (<https://www.pgnz.org.nz/our-trading-arm-ps/>) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines (<http://www.nzulm.org.nz/sponsors>). Pharmacodes and CTPP codes must be provided to Pharmac by the 5<sup>th</sup> of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest). Pharmac cannot list a product (and Pharmacies cannot claim) without the correct Pharmacode.



**2025/26 Invitation to Tender – Principal Supply Status applies until 30 June 2029**

**Community Pharmaceutical tenders – Section B of the Pharmaceutical Schedule**

1. *Tenders awarded to currently listed pharmaceuticals where no other brand is listed (no brand change).*

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	Date of subsidy change	Principal Supply date
Paraffin	White soft; 450 g pot	\$4.74	\$4.70	EVARA White Soft Paraffin (Evara)	1 September 2026	1 February 2027
Rosuvastatin <sup>1</sup>	Tab 5 mg; 30 tablet bottle	\$1.29	<del>\$0.98</del> \$0.76	Rosuvastatin Viatris (Viatris)	1 October 2026	1 March 2027
Rosuvastatin <sup>1</sup>	Tab 10 mg; 30 tablet bottle	\$1.69	\$0.98	Rosuvastatin Viatris (Viatris)	1 October 2026	1 March 2027
Rosuvastatin <sup>1</sup>	Tab 20 mg; 30 tablet bottle	\$2.71	\$1.37	Rosuvastatin Viatris (Viatris)	1 October 2026	1 March 2027
Rosuvastatin <sup>1</sup>	Tab 40 mg; 30 tablet bottle	\$4.55	\$2.24	Rosuvastatin Viatris (Viatris)	1 October 2026	1 March 2027
Thiotepa <sup>2</sup>	Inj 15 mg vial; 1 vial pack	\$398.00	\$278.60	Tepadina (Arrotex)	1 October 2026	1 March 2027
Thiotepa <sup>2</sup>	Inj 100 mg vial; 1 vial pack	\$1,800.00	\$1,260.00	Tepadina (Arrotex)	1 October 2026	1 March 2027

Ursodeoxycholic acid	Cap 250 mg; 100 capsule blister pack	\$33.95	\$33.45	Ursosan (Boucher)	1 September 2026	1 February 2027
<p><sup>1</sup>Pharmac tendered rosuvastatin tablets for both current and widened access. Pharmac has made the decision to award the widened access tenders. This means that the Special Authority and Hospital Restrictions on rosuvastatin tab 5 mg, tab 10 mg, tab 20 mg and tab 40 mg will be removed from 1 October 2026. The pack size for rosuvastatin tab 5 mg, tab 10 mg, tab 20 mg and tab 40 mg will change from 30 tablets to 90 tablets from 1 August 2027. From 1 February 2027 until 1 August 2027, both a 30 tablet and 90 tablet bottle of the Rosuvastatin Viatris brand of rosuvastatin tablets will be listed on the Pharmaceutical Schedule, after which the 30 tablet bottle will be delisted. Full details of the <a href="#">decision to open list rosuvastatin</a>.</p> <p><sup>2</sup>This product will be supplied at the Price from the 1st day of the month prior to the listing date, as per Schedule 4 clause 2.3(c)(ii) of the 2025/26 Invitation to Tender.</p>						

2. *Tenders awarded to pharmaceuticals where at least one other brand is listed (the funded brand will change).*

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	Date of subsidy change	Principal Supply date	Brand (Supplier) affected by delisting
Cyclopentolate hydrochloride <sup>1</sup>	Eye drops 1%, single dose; 20 plastic ampoule pack	\$68.52 (per 15 ml OP)*	\$46.00	Minims (Bausch and Lomb)	1 October 2026	1 March 2027	Cyclogyl (Alcon)
Losartan potassium	Tab 12.5 mg; 90 tablet blister pack	\$2.00 (per 84)	\$1.80	Ipca-Losartan (Miro)	1 January 2027	1 June 2027	Losartan Actavis (Teva)
Losartan potassium	Tab 25 mg; 90 tablet blister pack	\$2.29 (per 84)	\$2.10	Ipca-Losartan (Miro)	1 January 2027	1 June 2027	Losartan Actavis (Teva)
Losartan potassium	Tab 50 mg; 90 tablet blister pack	\$2.86 (per 84)	\$2.60	Ipca-Losartan (Miro)	1 January 2027	1 June 2027	Losartan Actavis (Teva)
Losartan potassium	Tab 100 mg; 90 tablet blister pack	\$4.57 (per 84)	\$4.26	Ipca-Losartan (Miro)	1 January 2027	1 June 2027	Losartan Actavis (Teva)
Naltrexone hydrochloride	Tab 50 mg; 30 tablet blister pack	\$83.33	\$69.03	Naltrexone Lupin (Lupin)	1 November 2026	1 April 2027	Naltraccord (Teva)
Tropicamide <sup>1</sup>	Eye drops 0.5%, single dose; 20 plastic ampoule pack	\$33.89 (per 15 ml OP)*	\$46.00	Minims (Bausch and Lomb)	1 October 2026	1 March 2027	Mydriacyl (Alcon)

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	Date of subsidy change	Principal Supply date	Brand (Supplier) affected by delisting
Tropicamide <sup>1</sup>	Eye drops 1%, single dose; 20 plastic ampoule pack	\$54.71 (per 15 ml OP)*	\$46.00	Minims (Bausch and Lomb)	1 October 2026	1 March 2027	Mydriacyl (Alcon)
<sup>1</sup> Please note the funded brands of cyclopentolate hydrochloride and tropicamide eye drops are changing from a 15 ml dropper bottle to 20 single dose plastic ampoules. For the more details on the decision, please see below. *This price is listed from 1 July 2026							

### Hospital Pharmaceutical tenders – Section H of the Pharmaceutical Schedule.

#### 3. Tenders awarded to currently listed pharmaceuticals where no other brand is listed (no brand change)

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	DV Limit	Date of subsidy change	Principal Supply date
Paraffin	White soft; 450 g pot	\$4.74	\$4.70	EVARA White Soft Paraffin (Evara)	5%	1 September 2026	1 February 2027
Rosuvastatin <sup>1</sup>	Tab 5 mg; 30 tablet blister pack	\$1.29	\$0.76	Rosuvastatin Viatris (Viatris)	5%	1 October 2026	1 March 2027
Rosuvastatin <sup>1</sup>	Tab 10 mg; 30 tablet blister pack	\$1.69	\$0.98	Rosuvastatin Viatris (Viatris)	5%	1 October 2026	1 March 2027
Rosuvastatin <sup>1</sup>	Tab 20 mg; 30 tablet blister pack	\$2.71	\$1.37	Rosuvastatin Viatris (Viatris)	5%	1 October 2026	1 March 2027
Rosuvastatin <sup>1</sup>	Tab 40 mg; 30 tablet blister pack	\$4.55	\$2.24	Rosuvastatin Viatris (Viatris)	5%	1 October 2026	1 March 2027
Thiotepa <sup>2</sup>	Inj 15 mg vial; 1 vial pack	\$398.00	\$278.60	Tepadina (Arrotex)	5%	1 October 2026	1 March 2027
Thiotepa <sup>2</sup>	Inj 100 mg vial; 1 vial pack	\$1,800.00	\$1,260.00	Tepadina (Arrotex)	5%	1 October 2026	1 March 2027

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	DV Limit	Date of subsidy change	Principal Supply date
Ursodeoxycholic acid	Cap 250 mg; 100 capsule blister pack	\$33.95	\$33.45	Ursosan (Boucher)	5%	1 September 2026	1 February 2027
<p><sup>1</sup>Pharmac tendered rosuvastatin tablets for both current and widened access. Pharmac has made the decision to award the widened access tenders. This means that the Special Authority and Hospital Restrictions on rosuvastatin tab 5 mg, tab 10 mg, tab 20 mg and tab 40 mg will be removed from 1 October 2026. The pack size for rosuvastatin tab 5 mg, tab 10 mg, tab 20 mg and tab 40 mg will change from 30 tablets to 90 tablets from 1 August 2027. From 1 February 2027 until 1 August 2027, both a 30 tablet and 90 tablet bottle of the Rosuvastatin Viatris brand of rosuvastatin tablets will be listed on the Pharmaceutical Schedule, after which the 30 tablet bottle will be delisted. Full details of the <a href="#">decision to open list rosuvastatin</a>.</p> <p><sup>2</sup>This product will be supplied at the Price from the 1st day of the month prior to the listing date, as per Schedule 4 clause 2.3(c)(ii) of the 2025/26 Invitation to Tender.</p>							

4. *Tenders awarded to pharmaceuticals where at least one other brand is listed (the funded brand will change).*

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	Date of subsidy change	Principal Supply date	Brand (Supplier) affected by delisting
Cyclopentolate hydrochloride <sup>1</sup>	Eye drops 1%, single dose; 20 plastic ampoule pack	\$68.52 (per 15 ml OP)*	\$46.00	Minims (Bausch and Lomb)	1 October 2026	1 March 2027	Cyclogyl (Alcon)
Granisetron	Inj 1 mg per ml, 3 ml ampoule; 1 glass ampoule pack	\$1.20	\$1.71	Granisetron-AFT (AFT)	1 August 2026	1 January 2027	Deva (Devatis)
Losartan potassium	Tab 12.5 mg; 90 tablet blister pack	\$2.00 (per 84)	\$1.80	Ipca-Losartan (Miro)	1 January 2027	1 June 2027	Losartan Actavis (Teva)
Losartan potassium	Tab 25 mg; 90 tablet blister pack	\$2.29 (per 84)	\$2.10	Ipca-Losartan (Miro)	1 January 2027	1 June 2027	Losartan Actavis (Teva)
Losartan potassium	Tab 50 mg; 90 tablet blister pack	\$2.86 (per 84)	\$2.60	Ipca-Losartan (Miro)	1 January 2027	1 June 2027	Losartan Actavis (Teva)
Losartan potassium	Tab 100 mg; 90 tablet blister pack	\$4.57 (per 84)	\$4.26	Ipca-Losartan (Miro)	1 January 2027	1 June 2027	Losartan Actavis (Teva)

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	Date of subsidy change	Principal Supply date	Brand (Supplier) affected by delisting
Naltrexone hydrochloride	Tab 50 mg; 30 tablet blister pack	\$83.33	\$69.03	Naltrexone Lupin (Lupin)	1 November 2026	1 April 2027	Naltraccord (Teva)
Tropicamide <sup>1</sup>	Eye drops 0.5%, single dose; 20 plastic ampoule pack	\$33.89 (per 15 ml OP)*	\$46.00	Minims (Bausch and Lomb)	1 October 2026	1 March 2027	Mydriacyl (Alcon)
Tropicamide <sup>1</sup>	Eye drops 1%, single dose; 20 plastic ampoule pack	\$54.71 (per 15 ml OP)*	\$46.00	Minims (Bausch and Lomb)	1 October 2026	1 March 2027	Mydriacyl (Alcon)
<sup>1</sup> Please note the funded brands of cyclopentolate hydrochloride and tropicamide eye drops are changing from a 15 ml dropper bottle to 20 single dose plastic ampoules. For the more details on the decision, please see below. *This will be the listed price from 1 July 2026.							

### Tender declines – Products where no tender is to be awarded for Principal Supply Status

Pharmac has resolved not to award tenders for Principal Supply Status for the following products listed in the 2025/26 Invitation to Tender, dated 3 November 2025.

Chemical Name	Line Item
Rosuvastatin (current access)	Tab 5 mg
Rosuvastatin (current access)	Tab 10 mg
Rosuvastatin (current access)	Tab 20 mg
Rosuvastatin (current access)	Tab 40 mg

## Rosuvastatin

### What's changing?

We are pleased to announce our decision to remove the Special Authority and Hospital Restrictions on rosuvastatin tab 5 mg, tab 10 mg, tab 20 mg and tab 40 mg from **1 October 2026**.

We are also announcing that the pack size for rosuvastatin tab 5 mg, tab 10 mg, tab 20 mg and tab 40 mg will change from 30 tablets to 90 tablets from **1 August 2027**. From **1 February 2027 until 1 August 2027**, both a 30 tablet and 90 tablet bottle of the Rosuvastatin Viatris brand of rosuvastatin tablets will be listed on the Pharmaceutical Schedule, after which the 30 tablet bottle will be delisted.

There are currently two funded brands of rosuvastatin, Rosuvastatin Viatris and Rosuvastatin – Sandoz and another alternative brand, Rosuvastatin Mylan, will also be listed on the Pharmaceutical Schedule from 1 July 2026 to support consistent supply for patients. On **1 March 2027**, the Rosuvastatin - Sandoz and Rosuvastatin Mylan brands of rosuvastatin tablets will be delisted from Section B and Part II of Section H of the Pharmaceutical Schedule and the Rosuvastatin Viatris brand will be the main funded brand of rosuvastatin tablets.

From **1 March 2027 until 1 August 2027**, both the 30 tablet bottle and 90 tablet bottle of the Rosuvastatin Viatris brand of rosuvastatin tablets will have Principal Supply Status. On **1 August 2027**, the 30 tablet bottle of the Rosuvastatin Viatris brand of rosuvastatin tablets will be delisted from Section B and Part II of Section H of the Pharmaceutical Schedule. From **1 August 2027 until 30 June 2029**, the 90 tablet bottle of the Rosuvastatin Viatris brand of rosuvastatin tablets will have Principal Supply Status. This means that Rosuvastatin Viatris will be the main funded brand of rosuvastatin tablets until 30 June 2029.

Full details of the [decision to open list rosuvastatin](#).

## Cyclopentolate hydrochloride and Tropicamide

### What's changing?

This decision will result in a change from 15 ml dropper bottles to packs of 20 × 0.5 ml single dose plastic ampoules for cyclopentolate hydrochloride and tropicamide eye drops.

This brand change will also change the storage requirements for tropicamide eye drops. The new Minims products require refrigeration (stored at 2–8 °C), whereas the current funded brand (Mydriacyl) does not. The refrigeration requirement for cyclopentolate hydrochloride eye drops remain unchanged (stored at 2–8 °C) for both the current brand (Cyclogyl) and the new Minims brand.

### Reason for Change

The brand change to single dose cyclopentolate hydrochloride and tropicamide eye drops is being made to supporting ongoing continuity of supply for these medicines. The currently funded brands (Cyclogyl and Mydriacyl, supplied in 15 ml bottles) are being discontinued for supply to the funded market by the manufacturer. Pharmac has been working with suppliers to manage this discontinuation and, through the 2025/26 Annual Invitation to Tender process, has secured supply of an alternative brand of cyclopentolate hydrochloride and tropicamide eye drops in single dose ampoule form. We will communicate more detail on this change closer to the time of the change of brand.